Foghorn Therapeutics Inc (FHTX) Stock Price, Quote & News

Company Profile

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cel...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 586 3100

Website: foghorntx.com

Address:

500 Technology Square, Suite 700, Cambridge, United States

JohnTrack Jan. 13 at 9:14 PM

$FHTX Closing of $50 Million Registered Direct Financing https://www.rapidticker.com/news/fhtx-foghorn-therapeutics-announces-closing-of-9ca5bf

0 · Reply

oneyedjacks Jan. 12 at 8:29 PM

$FHTX I Say I say Bullish

0 · Reply

vu_jade Jan. 12 at 7:46 PM

$FHTX howdy

0 · Reply

LabPsycho Jan. 12 at 6:50 PM

$FHTX $PRLD @Stmkr mysteriously prld pause smarca2 = 100% price increase. Something else seems to be going on? I've posted my conspiracy theories for rebuking. Worst part is all the time I wasted creating a simulation with their molecule. Maybe I should work on a molecular model for FHTX...however such a huge time and effort drain in the research and set up required to get one to work and hardly anyone seems to care about these molecular dynamic simulations I post. Hmm...what to do?

0 · Reply

OpenOutcrier Jan. 12 at 1:54 PM

$FHTX (+6.4% pre) Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 https://ooc.bz/l/89377

0 · Reply

AlertsAndNews Jan. 11 at 11:40 PM

$FHTX Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 "Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026"

0 · Reply

Stmkr Jan. 10 at 5:38 AM

$FHTX Surprisingly good cash raise. But I am skeptical of their lead SMARCA2 program following prior failures, including pausing of SMARCA2 program by $PRLD

2 · Reply

outlawinvestor1 Jan. 7 at 1:30 PM

$CCCC $ARVN $FHTX multiple tpd tickers remain undervalued. $GLUE

0 · Reply

outlawinvestor1 Jan. 7 at 12:19 PM

$GLUE nice update for monte Rosa’s lead program. $ARVN $CCCC $FHTX exciting time for tpd space.

0 · Reply

ChemistryCharm Dec. 27 at 1:40 PM

$FHTX Market participants want evidence that strategy converts to numbers; organic growth must prove sustainable without incentives — any stumble could quickly widen valuation discounts. From here, results — not promises — will decide direction.

0 · Reply

Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium

Jan 9, 2026, 10:20 PM EST - 4 days ago

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Nov 25, 2025, 7:00 AM EST - 7 weeks ago

Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Nov 5, 2025, 7:00 AM EST - 2 months ago

Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update

Nov 3, 2025, 7:30 AM EST - 2 months ago

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

Oct 30, 2025, 8:56 PM EDT - 2 months ago

Foghorn Therapeutics Inc. (FHTX) Discusses Pipeline Updates for Selective ARID1B, CBP and EP300 Degrader Programs Transcript

Oct 30, 2025, 7:30 AM EDT - 2 months ago

Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs

Oct 16, 2025, 7:00 AM EDT - 3 months ago

Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit

Aug 28, 2025, 8:00 AM EDT - 4 months ago

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

IQV MRNA SANA

Aug 5, 2025, 7:00 AM EDT - 5 months ago

Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update

May 22, 2025, 7:00 AM EDT - 8 months ago

Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences

May 14, 2025, 7:00 AM EDT - 8 months ago

Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update

May 5, 2025, 7:00 AM EDT - 9 months ago

Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference

May 1, 2025, 7:00 AM EDT - 9 months ago

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

Apr 28, 2025, 4:05 PM EDT - 9 months ago

Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update

Apr 15, 2025, 7:00 AM EDT - 9 months ago

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting

Mar 25, 2025, 4:35 PM EDT - 10 months ago

Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting

Mar 6, 2025, 4:05 PM EST - 11 months ago

Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook

Feb 25, 2025, 7:00 AM EST - 11 months ago

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

Dec 16, 2024, 7:00 AM EST - 1 year ago

Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities

Nov 4, 2024, 4:05 PM EST - 1 year ago

Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update

Oct 10, 2024, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors

Oct 1, 2024, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics to Participate in the BMO Oncology Summit

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer

Aug 28, 2024, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update

May 28, 2024, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June

May 22, 2024, 6:21 PM EDT - 1 year ago

Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline

May 20, 2024, 7:58 AM EDT - 1 year ago

Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants

May 6, 2024, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update

Apr 16, 2024, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer

Apr 9, 2024, 4:30 PM EDT - 1 year ago

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

Apr 5, 2024, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics to Participate in Needham's 23rd Annual Virtual Healthcare Conference

Mar 26, 2024, 7:00 AM EDT - 1 year ago

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

Mar 7, 2024, 7:00 AM EST - 2 years ago

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

Mar 5, 2024, 4:48 PM EST - 2 years ago

Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909

Feb 28, 2024, 7:00 AM EST - 2 years ago

Foghorn Therapeutics to Participate in Cowen's 44th Annual Health Care Conference

Dec 1, 2023, 7:00 AM EST - 2 years ago

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting

Nov 2, 2023, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update

Oct 13, 2023, 8:00 AM EDT - 2 years ago

Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress

Oct 4, 2023, 8:00 AM EDT - 2 years ago

Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

Sep 11, 2023, 6:30 AM EDT - 2 years ago

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

DNLI MCRB MRNA SANA

$Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML$

Aug 31, 2023, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML

Aug 16, 2023, 5:08 PM EDT - 2 years ago

Foghorn Therapeutics: Ifs, Buts, And Clinical Holds

Aug 4, 2023, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update

Jun 28, 2023, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma

Jun 21, 2023, 6:00 AM EDT - 2 years ago

Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs

DNLI MCRB MRNA SANA

Jun 7, 2023, 8:00 AM EDT - 2 years ago

Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences

$Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients$

Jun 5, 2023, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients

JohnTrack Jan. 13 at 9:14 PM

$FHTX Closing of $50 Million Registered Direct Financing https://www.rapidticker.com/news/fhtx-foghorn-therapeutics-announces-closing-of-9ca5bf

0 · Reply

oneyedjacks Jan. 12 at 8:29 PM

$FHTX I Say I say Bullish

0 · Reply

vu_jade Jan. 12 at 7:46 PM

$FHTX howdy

0 · Reply

LabPsycho Jan. 12 at 6:50 PM

0 · Reply

OpenOutcrier Jan. 12 at 1:54 PM

$FHTX (+6.4% pre) Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 https://ooc.bz/l/89377

0 · Reply

AlertsAndNews Jan. 11 at 11:40 PM

0 · Reply

Stmkr Jan. 10 at 5:38 AM

$FHTX Surprisingly good cash raise. But I am skeptical of their lead SMARCA2 program following prior failures, including pausing of SMARCA2 program by $PRLD

2 · Reply

outlawinvestor1 Jan. 7 at 1:30 PM

$CCCC $ARVN $FHTX multiple tpd tickers remain undervalued. $GLUE

0 · Reply

outlawinvestor1 Jan. 7 at 12:19 PM

$GLUE nice update for monte Rosa’s lead program. $ARVN $CCCC $FHTX exciting time for tpd space.

0 · Reply

ChemistryCharm Dec. 27 at 1:40 PM

0 · Reply

GenesisGains Dec. 27 at 5:36 AM

$FHTX Capital seems to prefer stability in metrics rather than volatile growth spurts. Forecast reliability has room to improve materially. Durability across environments would extend investor horizons. Ultimately, disciplined delivery will shape the outcome.

0 · Reply

CoalKingpin Dec. 24 at 10:50 AM

$FHTX Current positioning will be tested as strategic priorities translate into measurable operating outcomes. The window for proof-of-execution is narrowing.

0 · Reply

OfficialStocktwitsUser Dec. 23 at 4:09 PM

$FHTX RSI: 78.83, MACD: 0.2319 Vol: 0.43, MA20: 4.69, MA50: 4.47 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

AnomalyDetective Dec. 22 at 6:07 PM

$FHTX the first of the Week 52 MDA picks for members to break 10% through Monday in this short trading week. Many more prior MDA breakout picks available at top.vmbreakouts.com Credit: vmbreakouts.com @vmbreakouts More on the new 2026 portfolios here: https://seekingalpha.com/mp/1201-value-momentum-breakouts/articles/6238776-a-glimpse-of-portfolios-to-come-for-2026

0 · Reply

notreload_ai Dec. 18 at 5:27 PM

$ALMS , $FHTX , $LXEO ... Analysts highlight Alumis, Foghorn, and Lexeo as biotech stocks with strong clinical catalysts and significant upside potential into 2026. https://notreload.xyz/biotech-analyst-picks-signal-major-upside-into-2026/

0 · Reply

vu_jade Dec. 18 at 5:00 PM

$FHTX is this the “Leg Horn” part?

0 · Reply

JarvisFlow Dec. 18 at 12:19 PM

BTIG has updated their rating for Foghorn Therapeutics ( $FHTX ) to Buy with a price target of 11.

0 · Reply

SuperGreenToday Dec. 17 at 9:51 PM

$FHTX Share Price: $4.63 Contract Selected: Jun 18, 2026 $5 Calls Buy Zone: $0.72 – $0.89 Target Zone: $1.26 – $1.54 Potential Upside: 65% ROI Time to Expiration: 182 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Baerchen Dec. 17 at 6:18 PM

$FHTX prelude was working afasi on a single asset-therapy - when working through fhtx-presentation, you easily spot, they take their smarca2 with name olomorasib and 2 further lly-assets as well as with chemo-standard. Only one positive trial will get new SOC. There is a reason why LLY does this and probably spent even more. It is the same as it was in KRAS. Many failed - but once a therapy got breakthrough, they lead. From all bios out in the stock market - this is a gem.

1 · Reply

theBigDollarski Dec. 16 at 3:20 PM

$FHTX this is so cheep it's laughable.

0 · Reply

Woodmont Dec. 16 at 12:51 PM

$FHTX If the lead drug is proven effective, LLY will buy the whole company at 10x from where we are sitting today, slowly accumulating good luck!!!

0 · Reply

vu_jade Dec. 8 at 8:42 PM

$FHTX Doing some Leghorn work

0 · Reply

Market Cap	360.80M
Revenue (ttm)	22.60M
Net Income (ttm)	-86.62M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-383.27%
Debt to Equity Ratio	0.00

Volume	434,773
Avg Vol	195,678
Day's Range	N/A - N/A
Shares Out	56.55M
Stochastic %K	88%
Beta	3.05
Analysts	Strong Sell
Price Target	$11.67